Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

AIMS: To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme. MATERIALS AND METHODS: The SUSTAIN clinical trial programme evaluated the efficacy and safety of semaglutide, a glucagon‐like peptide‐1 analogue, for the treatment of type 2 diabetes (T2D). In SUSTAIN...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Diabetes Obes Metab
Hoofdauteurs: Vilsbøll, Tina, Bain, Stephen C., Leiter, Lawrence A., Lingvay, Ildiko, Matthews, David, Simó, Rafael, Helmark, Ida Carøe, Wijayasinghe, Nelun, Larsen, Michael
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Blackwell Publishing Ltd 2018
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888154/
https://ncbi.nlm.nih.gov/pubmed/29178519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13172
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items